CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3 MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Government regulations
3.3.1. Center for Veterinary Medicine (CVM)
3.3.2. Environmental Protection Agency (EPA)
3.4. Patents Analysis
3.4.1. PATENT ANALYSIS BY YEAR
3.4.1.1. Patent analysis of animal therapeutics by year
3.4.1.2. Patent analysis of animal diagnostics by year
3.4.2. PATENT ANALYSIS BY REGION
3.4.2.1. Patent analysis of animal diagnostics by region
3.4.2.2. Patent analysis of animal diagnostics by region
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rising demand for animal derived food products
3.5.1.2. Growing demand for pet insurance
3.5.1.3. Rising concern to prevent zoonotic diseases
3.5.1.4. Growing ownership of companion animals
3.5.1.5. Rising animal health expenditure
3.5.2. Restraints
3.5.2.1. Highly competitive meat and milk prices
3.5.2.2. Lack of animal health awareness
3.5.2.3. Adverse impact of veterinary drugs on human and animal health
3.5.3. Opportunities
3.5.3.1. Advancement in therapeutic and diagnostic products
3.5.3.2. Therapeutic and diagnostic products for hybrid animals
CHAPTER 4 ANIMAL THERAPEUTICS AND DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. animal diagnostics products
4.2.1. Market size and forecast
4.2.2. Instruments
4.2.2.1. Key market trends
4.2.2.2. Key growth factors and opportunities
4.2.3. Consumables
4.2.3.1. Key market trends
4.2.3.2. Key growth factors and opportunities
4.3. animal therapeutics products
4.3.1. Market size and forecast
4.3.2. Anti-Parasitic drugs and antibiotics
4.3.2.1. Key market trends
4.3.2.2. Key growth factors and opportunities
4.3.3. Anti-Inflammatory drugs
4.3.3.1. Key market trends
4.3.3.2. Key growth factors and opportunities
4.3.4. Anesthetics
4.3.4.1. Key market trends
4.3.4.2. Key growth factors and opportunities
4.3.5. Others
4.3.5.1. Key market trends
4.3.5.2. Key growth factors and opportunities
CHAPTER 5 ANIMAL THERAPEUTICS AND DIAGNOSTICS MARKET, BY ANIMAL TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Companion Animals
5.2.1. Market size and forecast
5.2.2. Dogs
5.2.3. Cats
5.2.4. Other Companion Animals
5.3. Cattle
5.3.1. Market size and forecast
5.4. Pigs
5.4.1. Market size and forecast
5.5. Poultry
5.5.1. Market size and forecast
5.6. Sheep
5.6.1. Market size and forecast
CHAPTER 6 ANIMAL THERAPEUTICS AND DIAGNOSTICS MARKET, BY GEOGRAPHY
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size & forecast
6.2.5. Canada market size and forecast
6.2.6. Mexico market size and forecast
6.3. Europe
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany market size and forecast
6.3.5. France market size and forecast
6.3.6. UK market size and forecast
6.3.7. Italy market size and forecast
6.3.8. Rest of Europe market size and forecast
6.4. Asia-Pacific
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan market size and forecast
6.4.5. China market size and forecast
6.4.6. Australia market size and forecast
6.4.7. India market size and forecast
6.4.8. South Korea market size and forecast
6.4.9. Taiwan market size and forecast
6.4.10. Rest of Asia-Pacific market size and forecast
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size and forecast
6.5.5. Turkey market size and forecast
6.5.6. Venezuela market size and forecast
6.5.7. Saudi Arabia market size and forecast
6.5.8. Rest of LAMEA market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. Bayer AG
7.1.1. Company overview
7.1.2. Operating business segments
7.1.3. Business performance
7.1.4. Key strategic moves & developments
7.2. Eli Lilly and Company
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Business performance
7.2.4. Key strategic moves & developments
7.3. Boehringer, Ingelheim GmbH
7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Business performance
7.4. Merck & Co.
7.4.1. Company overview
7.4.2. Business performance
7.4.3. Key strategic moves & developments
7.5. Zoetis Inc.
7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Business performance
7.6. Ceva Sant Animale
7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Business performance
7.7. Sanofi S.A.
7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Business performance
7.7.4. Key strategic moves & developments
7.8. Nutreco N.V.
7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Business performance
7.9. Virbac S.A.
7.9.1. Company overview
7.9.2. Business performance
7.9.3. Key strategic moves & development
*Details on financial performance, strategic moves and developments may not be captured for unlisted companies.
*Please note this is a tentative TOC and may change with research proceedings.